Transcatheter Technologies GMBH
Truly repositionable transcatheter aortic valve implant
This article was originally published in Start Up
Executive Summary
A major limitation of existing transcatheter aortic heart valves is that they are unable to be repositioned once implanted. For these devices, the valve is mounted in a metal stent that contains a balloon, which is inflated once the valve is placed. The valve is then anchored to the heart wall. Transcatheter Technologies GMBH believes its fully repositionable Trinity valve will solve this shortcoming. Once Trinity is initially placed, cardiac surgeons or interventionalists can evaluate the valve function to determine whether the valve needs to be repositioned, retrieved or kept in the same position. Moreover, it allows for a controlled positioning, by slowly opening the valve stent, for a likely first-attempt correct placement.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.